Chloroquine hype hinders other trials
The fervour surrounding hydroxychloroquine has created drug shortages and affected enrolment in clinical trials for potential COVID-19 treatments. Interest in hydroxychloroquine (and its close chemical cousin chloroquine) has been spurred by preliminary studies and added publicity from political leaders such as US President Donald Trump and French President Emmanuel Macron. So far, data backing the drugs’ efficacy have been limited. Now, trials of promising treatments are butting up against people’s preference for the well-known option. “There’s a tremendous bias,” says neurologist Sergio Iván Valdés-Ferrer, who is studying the effects of a dementia drug on COVID-19. “Studies of any other drug that are enrolling all ages and degrees of severity are in big trouble.”
Nature | 6 min read
.png)
No hay comentarios:
Publicar un comentario